Glucagon-like peptide-1 receptor agonists (GLP‑1 Ras) — such as semaglutide and liraglutide — are celebrated for producing weight-loss results comparable to bariatric surgery, improving glucose control, and reducing cardiovascular risk. Yet new questions are surfacing about what users may be losing, besides fat. A recent narrative review in the Journal of Clinical Endocrinology & Metabolism warns […]
